MX2017010595A - Métodos, composiciones, y equipos para tratamiento de cáncer. - Google Patents
Métodos, composiciones, y equipos para tratamiento de cáncer.Info
- Publication number
- MX2017010595A MX2017010595A MX2017010595A MX2017010595A MX2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A MX 2017010595 A MX2017010595 A MX 2017010595A
- Authority
- MX
- Mexico
- Prior art keywords
- kits
- compositions
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118350P | 2015-02-19 | 2015-02-19 | |
| US201562150235P | 2015-04-20 | 2015-04-20 | |
| PCT/US2016/018634 WO2016134234A1 (en) | 2015-02-19 | 2016-02-19 | Methods, compositions, and kits for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010595A true MX2017010595A (es) | 2018-11-12 |
Family
ID=56689191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010595A MX2017010595A (es) | 2015-02-19 | 2016-02-19 | Métodos, composiciones, y equipos para tratamiento de cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160243228A1 (enExample) |
| EP (1) | EP3258966A4 (enExample) |
| JP (2) | JP6774421B2 (enExample) |
| KR (1) | KR20170137717A (enExample) |
| CN (1) | CN107635583A (enExample) |
| AU (2) | AU2016219917B2 (enExample) |
| BR (1) | BR112017017700A2 (enExample) |
| CA (1) | CA2976638A1 (enExample) |
| IL (1) | IL253979B (enExample) |
| MX (1) | MX2017010595A (enExample) |
| SG (1) | SG11201706727XA (enExample) |
| WO (1) | WO2016134234A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2549769T3 (es) | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| AU2016374441B2 (en) | 2015-12-17 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| CN110785184A (zh) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法，组合物和试剂盒 |
| CN108440673B (zh) * | 2018-04-08 | 2021-08-17 | 海南医学院 | Fc融合蛋白PD1/FGFR1及其应用 |
| US20200277387A1 (en) * | 2019-03-01 | 2020-09-03 | Rainier Therapeutics, Inc. | Methods and compositions for treating cancer |
| JP2023514795A (ja) * | 2019-06-03 | 2023-04-11 | フュージョン ファーマシューティカルズ インコーポレイテッド | がんを処置するための方法および組成物 |
| US20220348662A1 (en) * | 2019-09-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| KR20220157464A (ko) * | 2020-03-23 | 2022-11-29 | 퓨전 파마슈티칼즈 인크. | Fgfr3-표적화된 방사선면역접합체 및 그의 용도 |
| TW202229343A (zh) | 2020-08-21 | 2022-08-01 | 美商健臻公司 | Fgfr3抗體及使用方法 |
| WO2022092085A1 (ja) * | 2020-10-28 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073770A1 (es) * | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| ES2549769T3 (es) * | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| WO2012088266A2 (en) * | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| BR112015001724A2 (pt) * | 2012-07-27 | 2018-04-03 | Genentech Inc | métodos de tratamento de condições relacionadas a fgfr3 |
| TWI888366B (zh) * | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
-
2016
- 2016-02-19 SG SG11201706727XA patent/SG11201706727XA/en unknown
- 2016-02-19 CA CA2976638A patent/CA2976638A1/en active Pending
- 2016-02-19 AU AU2016219917A patent/AU2016219917B2/en active Active
- 2016-02-19 BR BR112017017700A patent/BR112017017700A2/pt not_active Application Discontinuation
- 2016-02-19 MX MX2017010595A patent/MX2017010595A/es unknown
- 2016-02-19 CN CN201680022780.7A patent/CN107635583A/zh active Pending
- 2016-02-19 KR KR1020177025882A patent/KR20170137717A/ko not_active Ceased
- 2016-02-19 WO PCT/US2016/018634 patent/WO2016134234A1/en not_active Ceased
- 2016-02-19 US US15/048,030 patent/US20160243228A1/en not_active Abandoned
- 2016-02-19 JP JP2017544657A patent/JP6774421B2/ja not_active Expired - Fee Related
- 2016-02-19 EP EP16753128.4A patent/EP3258966A4/en not_active Withdrawn
-
2017
- 2017-08-14 IL IL253979A patent/IL253979B/en active IP Right Grant
-
2020
- 2020-10-02 JP JP2020167443A patent/JP7122357B2/ja not_active Expired - Fee Related
-
2022
- 2022-01-13 AU AU2022200196A patent/AU2022200196B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ735243A (en) | 2024-11-29 |
| EP3258966A4 (en) | 2018-07-25 |
| IL253979A0 (en) | 2017-10-31 |
| JP2021020909A (ja) | 2021-02-18 |
| JP7122357B2 (ja) | 2022-08-19 |
| JP6774421B2 (ja) | 2020-10-21 |
| AU2022200196A1 (en) | 2022-02-10 |
| AU2016219917B2 (en) | 2021-12-16 |
| CA2976638A1 (en) | 2016-08-25 |
| US20160243228A1 (en) | 2016-08-25 |
| EP3258966A1 (en) | 2017-12-27 |
| CN107635583A (zh) | 2018-01-26 |
| SG11201706727XA (en) | 2017-09-28 |
| BR112017017700A2 (pt) | 2018-07-31 |
| WO2016134234A1 (en) | 2016-08-25 |
| AU2016219917A1 (en) | 2017-09-07 |
| AU2022200196B2 (en) | 2025-04-10 |
| JP2018507220A (ja) | 2018-03-15 |
| IL253979B (en) | 2021-06-30 |
| KR20170137717A (ko) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| BR112017017700A2 (pt) | métodos, composições e kits para tratamento do câncer | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| PH12016501550B1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| GEAP202014670A (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| AU2016263598A8 (en) | Methods and kits for treating depression | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX388409B (es) | Composiciones y metodos para tratar canceres. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| PH12017501880A1 (en) | Methods for treating cancer | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| NZ771363A (en) | Methods, compositions, and kits for treatment of cancer |